These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 27551518)

  • 1. Repositioning of a cyclin-dependent kinase inhibitor GW8510 as a ribonucleotide reductase M2 inhibitor to treat human colorectal cancer.
    Hsieh YY; Chou CJ; Lo HL; Yang PM
    Cell Death Discov; 2016; 2():16027. PubMed ID: 27551518
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acquired tamoxifen resistance is surmounted by GW8510 through ribonucleotide reductase M2 downregulation-mediated autophagy induction.
    Li ZN; Shu Y; Chen CG; Li XQ; Li MY; Zhao XH; Wang S; Li J
    Biochem Biophys Res Commun; 2020 Jul; 528(3):554-560. PubMed ID: 32505349
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gemcitabine resistance mediated by ribonucleotide reductase M2 in lung squamous cell carcinoma is reversed by GW8510 through autophagy induction.
    Chen P; Wu JN; Shu Y; Jiang HG; Zhao XH; Qian H; Chen K; Lan T; Chen CG; Li J
    Clin Sci (Lond); 2018 Jul; 132(13):1417-1433. PubMed ID: 29853661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic Interactions between GW8510 and Gemcitabine in an In Vitro Model of Pancreatic Cancer.
    Rüstem DG; Atay S; Aydin HH; Ak H
    Anticancer Agents Med Chem; 2021 Oct; 21(16):2204-2215. PubMed ID: 33397269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of CDK9 exhibits anticancer activity in hepatocellular carcinoma cells via targeting ribonucleotide reductase.
    Lin JC; Liu TP; Chen YB; Huang TS; Chen TY; Yang PM
    Toxicol Appl Pharmacol; 2023 Jul; 471():116568. PubMed ID: 37245555
    [TBL] [Abstract][Full Text] [Related]  

  • 6. E2F1 promote the aggressiveness of human colorectal cancer by activating the ribonucleotide reductase small subunit M2.
    Fang Z; Gong C; Liu H; Zhang X; Mei L; Song M; Qiu L; Luo S; Zhu Z; Zhang R; Gu H; Chen X
    Biochem Biophys Res Commun; 2015 Aug; 464(2):407-15. PubMed ID: 26093293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging roles of the ribonucleotide reductase M2 in colorectal cancer and ultraviolet-induced DNA damage repair.
    Lu AG; Feng H; Wang PX; Han DP; Chen XH; Zheng MH
    World J Gastroenterol; 2012 Sep; 18(34):4704-13. PubMed ID: 23002339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. P53 suppresses ribonucleotide reductase via inhibiting mTORC1.
    He Z; Hu X; Liu W; Dorrance A; Garzon R; Houghton PJ; Shen C
    Oncotarget; 2017 Jun; 8(25):41422-41431. PubMed ID: 28507282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CREB1 directly activates the transcription of ribonucleotide reductase small subunit M2 and promotes the aggressiveness of human colorectal cancer.
    Fang Z; Lin A; Chen J; Zhang X; Liu H; Li H; Hu Y; Zhang X; Zhang J; Qiu L; Mei L; Shao J; Chen X
    Oncotarget; 2016 Nov; 7(47):78055-78068. PubMed ID: 27801665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ribonucleotide reductase small subunit M2 serves as a prognostic biomarker and predicts poor survival of colorectal cancers.
    Liu X; Zhang H; Lai L; Wang X; Loera S; Xue L; He H; Zhang K; Hu S; Huang Y; Nelson RA; Zhou B; Zhou L; Chu P; Zhang S; Zheng S; Yen Y
    Clin Sci (Lond); 2013 May; 124(9):567-78. PubMed ID: 23113760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ribonucleotide reductase M2 subunit expression and prognostic value in nasopharyngeal carcinoma.
    Han P; Lin ZR; Xu LH; Zhong Q; Zhu XF; Liang FY; Cai Q; Huang XM; Zeng MS
    Mol Med Rep; 2015 Jul; 12(1):401-9. PubMed ID: 25695839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. miR-211 regulates the expression of
    Chang CC; Lin CC; Wang CH; Huang CC; Ke TW; Wei PL; Yeh KT; Hsu KC; Hsu NY; Cheng YW
    Oncol Lett; 2018 May; 15(5):8107-8117. PubMed ID: 29731918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prognostic value of ribonucleotide reductase small subunit M2 in predicting recurrence for prostate cancers.
    Huang Y; Liu X; Wang YH; Yeh SD; Chen CL; Nelson RA; Chu P; Wilson T; Yen Y
    Urol Oncol; 2014 Jan; 32(1):51.e9-19. PubMed ID: 24360663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RRM2 is a potential prognostic biomarker with functional significance in glioma.
    Sun H; Yang B; Zhang H; Song J; Zhang Y; Xing J; Yang Z; Wei C; Xu T; Yu Z; Xu Z; Hou M; Ji M; Zhang Y
    Int J Biol Sci; 2019; 15(3):533-543. PubMed ID: 30745840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of hepatitis B virus replication by targeting ribonucleotide reductase M2 protein.
    Liu X; Xu Z; Hou C; Wang M; Chen X; Lin Q; Song R; Lou M; Zhu L; Qiu Y; Chen Z; Yang C; Zhu W; Shao J
    Biochem Pharmacol; 2016 Mar; 103():118-28. PubMed ID: 26774458
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Silencing RRM2 inhibits multiple myeloma by targeting the Wnt/β‑catenin signaling pathway.
    Liu X; Peng J; Zhou Y; Xie B; Wang J
    Mol Med Rep; 2019 Sep; 20(3):2159-2166. PubMed ID: 31322175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ribonucleotide reductase M2 (RRM2): Regulation, function and targeting strategy in human cancer.
    Zuo Z; Zhou Z; Chang Y; Liu Y; Shen Y; Li Q; Zhang L
    Genes Dis; 2024 Jan; 11(1):218-233. PubMed ID: 37588202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Expression of Ribonucleotide Reductase M2 in Patients with Multiple Myeloma and Its Mechanism Inhibiting Tumor Cell Proliferation].
    Liu X; Chen L; Fan LP; Cheng Z
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Apr; 28(2):540-546. PubMed ID: 32319393
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RRM2 Mediates the Anti-Tumor Effect of the Natural Product Pectolinarigenin on Glioblastoma Through Promoting CDK1 Protein Degradation by Increasing Autophagic Flux.
    Jiang H; Zhang D; Aleksandrovich KD; Ye J; Wang L; Chen X; Gao M; Wang X; Yan T; Yang H; Lu E; Liu W; Zhang C; Wu J; Yao P; Sun Z; Rong X; Timofeevich SA; Mahmutovich SS; Zheng Z; Chen X; Zhao S
    Front Oncol; 2022; 12():887294. PubMed ID: 35651787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting ribonucleotide reductase M2 subunit by small interfering RNA exerts anti-oncogenic effects in gastric adenocarcinoma.
    Kang W; Tong JH; Chan AW; Zhao J; Wang S; Dong Y; Sin FM; Yeung S; Cheng AS; Yu J; To K
    Oncol Rep; 2014 Jun; 31(6):2579-86. PubMed ID: 24756820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.